ROCHE Joelle



Laboratoire de Neurosciences Expérimentales et Cliniques
Bât. B36
Pôle Biologie Santé
1, rue Georges Bonnet
BP 633
86022 Poitiers Cedex

Tél : 05 49 45 40 23

e-mail :

Publications marquantes

1- Roche, J., Cenatiempo, Y. and Cozzone, A.J. The stringent response to inhibition of peptide chain initiation in Escherichia coli. FEBS Letters (1976) 71, 103-106.

2- Roche, J., Cenatiempo, Y. and Cozzone, A.J. The effects of trimethoprim and erythromycin on polysome metabolism in Escherichia coli. J. Antibiotics (1978) 31, 70-73.

3- Donini, P., Santonastaso, V., Roche, J. and Cozzone, A.J. The relationship between guanosine tetraphosphate, polysomes and RNA synthesis in amino acid starved Escherichia coli. Mol. Biol. Rep. (1978) 4, 15-19.

4- Roche, J., Cozzone, A.J., Donini, P. and Santonastaso, V. Differential effect of aminoacid starvation on polysome decay in Escherichia coli. Mol. Biol. Rep. (1978) 4, 21-24.

5- Balland, A., Roche, J. and Cozzone, A.J. Analysis of ribosome produced by polysome degradation in aminoacid starved Escherichia coli. FEMS Microbiol. Letters (1978) 3, 99-102.

6- Roche, J., Michel, S. and Cozzone, A.J. Electric behaviour of polysomes isolated from amino acid starved Escherichia coli. Biochimie (1979) 61, 961-965.

7- Lando, D., Secchi, J., Roche, J. and Raynaud, J.P. Adrenocorticotropin analogs and glucocorticoids in hypophysectomized rat. Effects on liver polyribosomes and rough endoplasmic reticulum. Endocrinology (1980) 107, 2055-2062.

8- Biard-Roche J, Gorka C and Lawrence JJ. The structural role of histone H1°: Comparison of binding properties of various H1 subfractions in reconstituted chromatin. EMBO J. (1982) 1, 1487-1492.

9- Chan D, Biard-Roche J, Gorka C, Girardet JL, Lawrence JJ and¬ Piette LH. The role of the central globular domain of histone H5 in chromatin structure. Journal of Biomolecular Structure and Dynamics (1984) 2, 319-332.

10- Roche J, Marion C, Gorka C, Roux B and Lawrence JJ. Electric birefringence of chromatin reconstituted with various H1 subfractions. Biochem. Biophys. Res. Commun. (1984) 121, 530-537.

11- Roche J, Gorka C, Goeltz P and Lawrence JJ. Histone H1° is associated with a gene repressed during liver development. Nature (1985) 314, 197-198.

12- Roche J, Girardet JL, Gorka C and Lawrence JJ. The involvement of Histone H1° in chromatin structure. Nucleic Acids Res. (1985) 13, 2843-2853.

13- Girardet JL and Roche J. Dynamic changes in chromatin superstructure: a light scattering study. Studia Biophysica (1985) 107, 13-21.

14- Marion C, Roche J, Roux B. and Gorka C. Differences in the condensation of chromatin by individual subfractions of histone H1. Implications for the role of H1° in the structural organization of chromatin. Biochemistry (1985) 24, 6328-6335.

15- Mazoyer S, Muller S, Morlé F and Roche J. Transient expression of chicken histone H5 in COS and HeLa cells. Mol. Cell. Biol. (Life Sci. Adv.) (1989) 8, 63-67.

17- Gourdon, G., Morlé, F., Roche, J., Tourneur, N., Joulain, V. and Godet, J. Identification of GATA-1 and NF-E2 binding sites in the flanking regions of the ¬human  globin genes. Acta Haematol. (1992) 87, 136-144.

18- Roche, J., Chaudun, E., Courtois, Y., Ferrag, F., Jeanny, S., Muller, S., Sanwal, M. and Counis, M.F. Histone deposition and metabolism in embryonic chick lenses during differentiation. Exp. Eye Res. (1992) 55, 183-187.

19- Michalon, P., Roche, J., Couturier, R., Favre-Bonvin, G. and Marion, C. DNase activity of micrococcal endonuclease covalently immobilized on nylon and polystyrene. Enz. Microbial Technology (1993) 15, 215-221.

20- J. Roche, E. Whisenant, F. Boldog, D. Loeb, J. Vance and H. Drabkin. Dinucleotide repeats flanking the hereditary renal carcinoma t(3;8) breakpoint at 3p14.2. Human Molecular Genetics (1994) 3, 215.

21- H. Drabkin, F. Boldog, J. Roche, S. Todd, M. Swanton, T. Varkony, G. Dessev, S. Li, B. Waggoner, W. Franklin, S. Naylor, K. Kok, C. Buys and R. Gemmill. Tumor suppressor loci from the short arm of chromosome 3. Journal of Lung Cancer (1994) 11, 153-154.

22- S. Todd, J. Roche, L. Hahner, R. Bolin, H. Drabkin and R. Gemmill. An 8 megabase YAC contig covering a chromosome 3p region deleted in the small cell lung cancer cell line U2020. Genomics (1995) 25, 19-28.

23- Roche, J., Boldog., F., Robinson, M., Robinson, L., Varella-Garcia, M., Swanton, M., Waggoner, B., Fishel, R., Franklin, W., Gemmill, R. and Drabkin, H. Distinct 3p21.3 deletions in lung cancer, analysis of deleted genes and identification of a new human semaphorin. Oncogene (1996) 12, 1289-1297.

24- Van den Berg, A, Hulsbeek, M., de Jong, D., Kok, K., Veldhuis, P., Roche, J. and Buys, C. Major role for a 3p21 region and lack of involvement of the t(3;8) breakpoint region in the development of renal cell carcinoma suggested by loss of heterozygosity analysis. Genes, Chromosomes and Cancer (1996) 15, 64-72.

25- Boldog, F., Gemmill, R., West, J., Robinson, M.; Robinson, L., Li, E., Roche, J., Todd, S., Waggonner, B., Lundstrom, J., Jacobson, J., Mullokandov, M., Klinger, H. and Drabkin, H. 3p14 homozygous deletions and sequence analysis of FRA3B. Human Molecular Genetics (1997) 6, 193-203.

26- Varella-Garcia, L., Brizard, F., Roche, J., Flandrin, G., Drabkin, H. and Brizard, A. AML1/ETO and PML/RARA rearrangements in a case of AML-M2 with a translocation t(15;17). Leukemia and Lymphoma (1999) 33, 403-406.

27- Hirsch, E., Hu, L-J., Prigent, A., Constantin, B., Agid, Y., Drabkin, H. and Roche, J.
Distribution of Semaphorin IV in adult human brain.
Brain Research (1999) 823, 67-79.

28- Brizard, F., Morel, F., Lacotte, L., Varella-Garcia, M., Roche, J., Drabkin, H. and Brizard, A. Réarrangements AML1/ETO et PML/RARA dans un cas de LAM2 avec translocation t(15;17)(q22;q12). Hématologie (1999) 5, 80-82.

29- Brambilla, E., Constantin, B., Drabkin, H., Roche, J. Semaphorin SEMA3F localization in malignant human lung and cell lines: a suggested role in cell adhesion and cell migration. American Journal of Pathology, (2000) 156, 939-950.

30- Calvo R, West J, Franklin W, Erickson P, Bemis L, Li E, Helfrich B, Bunn P, Roche J, Brambilla E, Rosell R, Gemmill R, Drabkin H. Altered HOX and WNT7A expression in human lung cancer. Proceedings of the National Academy of Sciences of USA, (2000) 97, 12776-12781.

31- Dahéron, L., Veinstein, A., Brizard, F., Drabkin, H., Lacotte, L., Guilhot, F., Larsen, CJ., Brizard, A. and Roche, J. The human LPP gene is fused to MLL in a secondary acute leukemia with a translocation t(3;11) (q28;q23). Genes Chromosome and Cancer, (2001) 31, 382-389.

32- Tomizawa, Y., Sekido, Y., Kondo, M., Yokota, J., Roche, J., Drabkin, H., Lerman, M., Gazdar, A. and Minna, J. Inhibition of lung cancer cell growth and induction of apoptosis after reexpression of 3p21.3 candidate tumor suppressor gene SEMA3B. Proceedings of the National Academy of Sciences of USA (2001) 98, 13954-13959.

33- Drabkin H, Parsy C, Ferguson K, Guilhot F, Lacotte L, Zend C, Baron A, Hunger S, Varella-Garcia M, Gemmill R, Brizard F, Brizard A, Roche J. Quantitative HOX expression in chromosomally defined subsets of acute myelogenous leukemia. Leukemia (2002) 16, 186-195.

34- Kusy S, Cividin M, Sorel N, Brizard F, Guilhot F, Brizard A, Larsen C and Roche J. p14ARF, p15INK4b and p16INK4a methylation status in chronic myelogenous leukemia. Blood (2003) 101, 374-375.

35- Lantuéjoul S, Constantin B, Drabkin H, Brambilla C, Roche J and Brambilla E. VEGF, Semaphorin SEMA3F and their common receptors neuropilins NP1 and NP2 expressions in preinvasive bronchial lesions, lung tumors and cell lines. Journal of Pathology (2003) 200, 336-347.

36- Nasarre P, Constantin B, Rouhaud L, Harnois T, Raymond G, Drabkin H, Bourmeyster N and Roche J. Semaphorin SEMA3F inhibits cell attachment and spreading in tumor cell lines. Neoplasia (2003) 5, 83-92.

37- Kusy S, Funkelstein L, Bourgais D, Drabkin H, Rougon G, Roche J and Castellani V. Redundant functions but region-specific regulation of two alternatively-spliced isoforms of Semaphorin 3F in the nervous system. Molecular and Cellular Neurosciences (2003) 24, 409-418.

38- Ohira T, Gemmill R, Ferguson, K, Kusy S, Roche J, Brambilla E, Zeng C, Baron A, Bemis L, Erickson P, Wilder E, Rustgi A, Kitajewski J, Gabrielson E, Bremnes R, Franklin W and Drabkin H. WNT7a induces E-cadherin in lung cancer cells. Proc. Natl. Acad. Sci. USA (2003) 100, 10429-10434.

39- Roche J, Zeng C, Baron A, Gadgil S, Gemmill R, Tigaud I, Thomas X and H Drabkin. Hox expression in AML identifies a distinct subset of patients with intermediate cytogenetics. Leukemia (2004) 18, 1059-63.

40- Kusy S, Larsen CJ and Roche J. p14ARF, p15INKAb and p16INK4a methylation status in chronic myelogenous leukemia. Leukemia and lymphoma (2004) 45, 1989-1994.

41- Nasarre P, Kusy S, Constantin B, Castellani V, Drabkin H, Bagnard D and Roche J. Semaphorin SEMA3F has a repulsing activity on breast cancer cells and inhibits E-cadherin-mediated cell adhesion. Neoplasia (2005) 7, 180-189.

42- Kusy S, Nasarre P, Chan D, Potiron V, Meyronet D, Gemmill R, Constantin B, Drabkin H and Roche J. Selective suppression of in vivo tumorigenicity by semaphorin SEMA3F in lung cancer cells. Neoplasia (2005) 7, 457-465.

43- Kusy S, Potiron V, Zeng C, Franklin W, Brambilla E, Minna J, Drabkin H and Roche J. Promoter characterization of semaphorin SEMA3F, a tumor suppressor gene. BBA Gene structure and expression (2005) 1730, 66-76.

44- Charrier C, Bertrand P, Gesson JP, Roche J. Synthesis of constrained trichostatin A analogs as HDAC inhibitors. Bioorganic and Medicinal Chemistry Letters (2006), 16, 5339-5344.

45- Thomas M, Rivault F, Tranoy-Opalinski I, Roche J, Gesson JP, Papot S. Synthesis and biological evaluation of the suberoylanilide hydroxamic acid (SAHA) β-glucuronide and β-galactoside for application in selective prodrug chemotherapy. Bioorganic and Medicinal Chemistry Letters (2007), 17, 983-986.

46- Loudni L, Roche J, Potiron V, Clarhaut J, Bachman C, Gesson JP, Tranoy-Opalinski I. Design, synthesis and biological evaluation of 1,4-benzodiazepine-2,5-dione-based HDAC inhibitors. Bioorganic and Medicinal Chemistry Letters (2007), 17, 4819-4823.

47- Potiron V, Sharma G, Nasarre P, Clarhaut J, Augustin H, Gemmill R, Roche J and Drabkin H. Semaphorin SEMA3F affects multiple signalling pathways in lung cancer cells. Cancer Research (2007), 67, 8708-8715.

48- Charrier C, Roche J, Gesson JP and Bertrand P. Antiproliferative activities of a library of hybrids between indanones and HDAC inhibitor SAHA and MS-275 analogues. Bioorganic and Medicinal Chemistry Letters (2007), 17, 6142-6146.

49- L Karayan, M Wager, J Guilhot, P Levillain, C Marquant, J Clarhaut, V Potiron and J Roche. Semaphorin, Neuropilin and VEGF expression in glial tumors: SEMA3G, a prognostic marker ? British Journal of Cancer (2008) 99, 1153-1160.

50- M Thomas, J Clarhaut, I Tranoy-Opalinski, JP Gesson, J Roche and S Papot.Synthesis and Biological Evaluation of Glucuronide Prodrugs of the Histone Deacetylase Inhibitor CI-994 for Application in Selective Cancer Chemotherapy. Bioorganic and Medicinal Chemistry (2008), 16, 8109-8116.

51- Clarhaut J, Gemmill R, Ait-Si-Ali S, Imbert J, Drabkin HA and Roche J. Semaphorin SEMA3F Tumor Suppressor Gene is Repressed by ZEB-1 in Lung Cancer Cells. Neoplasia (2009) 11, 157-166.

52- Charrier C, Clarhaut J, Gesson JP, Estiu G, Wiest O, Roche J, Bertrand P. Synthesis and modeling of new benzofuranone histone deacetylase inhibitors that stimulate tumor suppressor gene expression. J Med Chem (2009) 52, 3112-3115.

53- Charrier C, Roche J, Gesson JP, Bertrand P. Biological activities of substituted trichostatic derivatives. J Chem Sci (2009) 121, 471-479.

54- Gemmill R, Roche J, Potiron V, Nasarre P, Mitas M, Coldren C, Helfrich B, Garret-Mayer E, Bunn P, Drabkin H. ZEB1-responsive genes in non-small cell lung cancer. Cancer Letters (2011) 300, 66-78.

55- Thomas M, Clarhaut J, Strale PO, Tranoy-Opalinski, Roche J, Papot S. A galactosidase-responsive « trojan horse » for the selective targeting of folate receptor-positive tumor cells. Chem Med Chem (2011) 6, 1006-1010.

56- Roche J, Nasarre N, Gemmill R, Baldys A, Pontis J, Korch C, Guilhot J, Ait-Si-Ali S, Drabkin H. Global decrease of histone H3K27 acetylation in ZEB1-induced epithelial to mesenchymal transition in lung cancer cells. Special Issue “Cancer Epigenetics” in Cancers (2013) 5, 334-356.

En Révision :

Yoshida T, Gemmill R, Song L, Bai Y, Kinose F, Li J, Paraiso K, Ohaegbulam K, Muñoz-Antonia T, Qu X, Welsh E, Eschrich S, Oguz U, Fang B, Roche J, Drabkin H, Haura B. Comprehensive analysis to find the therapeutic targets against epithelial to mesenchymal transition-related acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in non-small cell lung cancer. En révision, Cancer Research.

Nasarre P, Gemmill R, Potiron V, Roche J, Lu X, Baron A, Korch C, Garrett-Mayer E, Lagana A, Howe P, Drabkin H. Neuropilin 2 is upregulated during transforming growth factor beta β1-induced epithelial mesenchymal transition in lung cancer. En révision, Cancer Research.


1- Mazoyer S, Roche J. L’histone H5: structure, expression et fonction. Chromatine: aspects structuraux et fonctionnels (1991), Marion, C. et Roche, J., Editions du CNRS, 179-192.

2- Mazoyer S, Roche J. Structure et expression des gènes d’histones dans le règne animal. Regard sur la Biochimie (1992) 1, 23-29.

3- Roche J, West J, Gemmill R, Drabkin H. Chromosome 3p, gènes suppresseurs de tumeurs et gènes de sémaphorines en 3p21.3. Médecine et Sciences (1998) 14, 283-290.

4- Roche J, Drabkin H. The role of semaphorins in lung cancer. Clinical Lung Cancer (2001) 3, 145-150.

5- Roche J, Drabkin H, Brambilla E. Neuropilin and its ligands in normal lung and cancer
Adv Exp Med Biol (2002) 515, 103-114.

6- Nasarre P, Roche J. Integrin pathways: a role for integrins in semaphorin signalling
In The ELSO Gazette: e-magazine of the European Life Science Organization
( Issue 17, Décembre 2003.

7- Nasarre P, Constantin B, Drabkin H, Roche J. Sémaphorines et cancers : état des lieux
Médecine et Sciences (2005) 21, 641- 647.

8- Potiron V, Roche J. Class-3 semaphorin signaling: the end of a dogma. Science’s STKE 2005, pe24 (2005).

9- Clarhaut J, Roche J, Drabkin H. Semaphorin in lung cancer. Journal of Thoracic Oncology (2006) 1, 203- 204.

10- Potiron V, Nasarre P, Roche J, Healy C, Boumsell L. Semaphorin signaling in the immune system. Adv Exp Med Biol (2007), 600, 132-144.

11- Potiron V, Drabkin H, Roche J. SEMA3F (sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3F). Atlas Genet Cytogenet Oncol Haematol. (2008)

12- Potiron VA, Roche J, Drabkin H . Semaphorins and their receptors in lung cancer. Cancer letters (2009) 273, 1-14.

13- Nasarre P, Potiron V, Drabkin H, Roche J. Guidance molecules in lung cancer. Cell Adhesion and Migration (2010) 4, 130-145.


1) « Chromatine: aspects structuraux et fonctionnels »: C Marion, MF Hacques, J Roche, 364 pages, Editions CNRS 1991

2) Co-editor with Dr Harry Drabkin of a special Focus on Lung Cancer in the review “Cell Adhesion and Migration”, Landes Biosciences, Ed D. Bagnard, 2010.

3) Letter from the guest editors, Joëlle Roche and Harry Drabkin, Cell Adhesion and Migration, Landes Biosciences, Ed D. Bagnard, 2010, 4, 94-95.


« Les sémaphorines », Les cibles membranaires de la cellule tumorale. Collection « Thérapie ciblée des cancers » 2ème partie, Directeur de collection : Pr A. Kahn, John Libey Eurotext Limited. 2010, 52-61.


« Conception de nouveaux médicaments anticancéreux pour une chimiothérapie ciblée ».
Patent CNRS : DI 03437-01
Inventors : Thomas M et Papot S.
Collaborators : Clarhaut J, Tranoy-Opalinski I et Roche J


Menu principal

Haut de page